Reply to E. Hindié

Document Type

Response or Comment

Publication Title

Journal of Clinical Oncology

Volume

39

Issue

8

First Page

944

Last Page

946

PubMed ID

33492998

Publisher

American Society of Clinical Oncology

School

School of Medical and Health Sciences

Funders

Merck & Co Inc

Comments

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., . . . Robert, C. (2021). Reply to E. Hindié [Correspondence]. Journal of Clinical Oncology, 39(8), 944-946. https://doi.org/10.1200/JCO.20.03463

Abstract

We thank Dr Hindié1 for her insightful comments and the pertinent question at the end of her deliberations. In our recent publication2 in the Journal of Clinical Oncology, we have demonstrated that the prolongation of recurrence-free survival (RFS) with pembrolizumab adjuvant therapy in the EORTC 1325/KEYNOTE-054 phase III trial, at a median follow-up of 3 years, is sustained and consistent in magnitude (hazard ratio [HR], 0.56) with the initially reported final analysis of this primary end point as published in 2018.3 In this trial, patients with melanoma were stratified as stage IIIA-B-C, according to the American Joint Committee on Cancer (AJCC)-7 staging system,4 with the specific prerequisite that stage IIIA patients must have a micrometastasis with a diameter > 1 mm according to the Rotterdam Criteria, to avoid a potentially large influx of patients with a very low risk of recurrence.

DOI

10.1200/JCO.20.03463

Access Rights

free_to_read

Link to Full Text

Share

 
COinS